| Nov 24, 2008 |
HIV+25 Survey Asks Where Are we in Canada Twenty-Five Years After Discovery of the Virus  |
|
Oct 26, 2008
|
New Phase III Study in previously untreated HIV patients showed Raltegravir reduced HIV viral load to undetectable levels, comparable to Efavirenz, when taken in combination with other medicines |
| Oct 7, 2008 |
Innovative HIV-AIDS treatment ISENTRESS™ now available to Canadian First Nations |
|
August 5, 2008
|
ISENTRESS™ (raltegravir), Merck Frosst's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts. Through 96 Weeks in Treatment-Naïve HIV-Infected Patients |
|
Nov 30, 2007
|
Health Canada Approves ISENTRESSTM (raltegravir)
Only drug to inhibit Integrase Enzyme
|
| July 24, 2007 |
Raltegravir in Combination Therapy Demonstrates Potent Antiretroviral Activity in Treatment-Naïve HIV-Positive Patients
|
| March 1, 2007 |
Results from Two Phase III Studies on Raltegravir, MK-0518,an Oral Investigational Integrase Inhibitor, Presented at the Annual Conference on Retroviruses and Opportunistic Infections |
